Cargando…

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression

The success of proteasome inhibition in multiple myeloma highlights the critical role for the ubiquitin-proteasome system (UPS) in this disease. However, there has been little progress in finding more specific targets within the UPS involved in myeloma pathogenesis. We previously found the ubiquitin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussain, Sajjad, Bedekovics, Tibor, Chesi, Marta, Bergsagel, P. Leif, Galardy, Paul J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747363/ https://www.ncbi.nlm.nih.gov/pubmed/26513019

Ejemplares similares

Walking the tightrope: UCH-L1 as an mTOR inhibitor and B-cell oncogene
por: Bedekovics, Tibor, et al.
Publicado: (2019)

A cysteine near the C-terminus of UCH-L1 is dispensable for catalytic activity but is required to promote AKT phosphorylation, eIF4F assembly, and malignant B-cell survival
por: Hussain, Sajjad, et al.
Publicado: (2019)

Chromosome instability in neuroblastoma: A pathway to aggressive disease
por: Paolini, Lucia, et al.
Publicado: (2022)

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma
por: Calcinotto, Arianna, et al.
Publicado: (2015)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Targeting UCHL1 Induces Cell Cycle Arrest in High-Risk Multiple Myeloma with t(4;14)
por: Kamseng, Parin, et al.
Publicado: (2021)

Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup
por: Wiedmeier-Nutor, Julia Erin, et al.
Publicado: (2022)

Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression
por: Calcinotto, Arianna, et al.
Publicado: (2018)

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014)

Multipeptide stimulated PBMCs generate T(EM)/T(CM) for adoptive cell therapy in multiple myeloma
por: Vardam-Kaur, Trupti, et al.
Publicado: (2021)

Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression
por: Croucher, Danielle C., et al.
Publicado: (2021)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS
por: Zhu, Shaochun, et al.
Publicado: (2019)

Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant
por: Meermeier, Erin W., et al.
Publicado: (2023)

Identification of PIKfyve kinase as a target in multiple myeloma
por: de Campos, Cecilia Bonolo, et al.
Publicado: (2020)

Aggressive Multiple Myeloma with Unusual Morphology
por: Sönmez, Mehmet, et al.
Publicado: (2014)

Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma
por: Villa, Nancy Y., et al.
Publicado: (2022)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma
por: Chng, WJ, et al.
Publicado: (2011)

Frequent occurrence of large duplications at reciprocal genomic rearrangement breakpoints in multiple myeloma and other tumors
por: Demchenko, Yulia, et al.
Publicado: (2016)

Mass Cytometry reveals unique phenotypic patterns associated with subclonal diversity and outcomes in multiple myeloma
por: Baughn, Linda B., et al.
Publicado: (2023)

The Diagnosis Value of Promoter Methylation of UCHL1 in the Serum for Progression of Gastric Cancer
por: Wang, Gongping, et al.
Publicado: (2015)

Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma
por: Rangel-Pozzo, Aline, et al.
Publicado: (2021)

Molecular Characterization and Expression Profiles of Sp-uchl3 and Sp-uchl5 during Gonad Development of Scylla paramamosain
por: Han, Kunhuang, et al.
Publicado: (2018)

UCHL1 expression and localization on testicular development and spermatogenesis of Chinese giant salamanders
por: Wang, Yuanxian, et al.
Publicado: (2017)

NLRP3 Regulates Mandibular Healing through Interaction with UCHL5 in MSCs
por: Zhao, Wenhua, et al.
Publicado: (2023)

UCHL1 from serum and CSF is a candidate biomarker for amyotrophic lateral sclerosis
por: Li, Ruibing, et al.
Publicado: (2020)

Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB
por: Demchenko, Yulia N., et al.
Publicado: (2014)

The deubiquitinase UCHL1 negatively controls osteoclastogenesis by regulating TAZ/NFATC1 signalling
por: Feng, Zhenhua, et al.
Publicado: (2023)

Hyperviscosity retinopathy as the initial presentation of aggressive multiple myeloma
por: Kuo, Hua-Hsuan, et al.
Publicado: (2020)

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2016)

Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression
por: Liu, Tao, et al.
Publicado: (2023)

UCHL1 regulates oxidative activity in skeletal muscle
por: Gao, Hongbo, et al.
Publicado: (2020)

Structural basis for specific inhibition of the deubiquitinase UCHL1
por: Grethe, Christian, et al.
Publicado: (2022)

Progress in multiple myeloma
por: Munker, Reinhold, et al.
Publicado: (2019)

UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance
por: Jin, Chengmeng, et al.
Publicado: (2013)

Deubiquitinase UCHL5 is elevated and associated with a poor clinical outcome in lung adenocarcinoma (LUAD)
por: Zhang, Jieru, et al.
Publicado: (2020)

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
por: Stein, Caleb K., et al.
Publicado: (2017)

UCHL1 protects against ischemic heart injury via activating HIF-1α signal pathway
por: Geng, Bingchuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o97plshlhq73ljdsp3ovet8mnk